Drug firm Strides Arcolab today said it has received the nod from the US Food and Drug Administration (USFDA) to sell Vecuronium Bromide injections, a muscle relaxant, in the US market.
The approval is for injections containing 10 mg and 20 mg of Vecuronium Bromide per vial, the company said in a statement.
Vecuronium Bromide is used to provide muscle relaxation during surgery or mechanical ventilation and last year in the US, sales of the injection totalled $10 million as per IMS data, it added.
The medicine will be launched in the near future under the joint venture between Strides and Akorn Inc, called Akorn-Strides, it said.
Strides is currently developing and supplying 22 injectable products for the US market. The products will be marketed by Akorn Inc.
The latest approval from the USFDA is the eighth approval that the company has received from the US health regulator in 2010.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app